<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">FURUBAYASHI, NOBUKI</style></author><author><style face="normal" font="default" size="100%">MOCHIDA, MANABU</style></author><author><style face="normal" font="default" size="100%">KIJIMA, ATSUHIRO</style></author><author><style face="normal" font="default" size="100%">FUJIMOTO, YUSHI</style></author><author><style face="normal" font="default" size="100%">NAKAMURA, MOTONOBU</style></author><author><style face="normal" font="default" size="100%">NEGISHI, TAKAHITO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Steroid Premedication Impact on Efficacy and Cutaneous Toxicity of Enfortumab Vedotin for Advanced Urothelial Carcinoma</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2025-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1607-1614</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.13961</style></doi><volume><style face="normal" font="default" size="100%">39</style></volume><issue><style face="normal" font="default" size="100%">3</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: The impact of steroid premedication on the efficacy and cutaneous toxicity of enfortumab vedotin (EV) in advanced urothelial carcinoma (UC) is unclear.Patients and Methods: We retrospectively analyzed consecutive patients with advanced UC who received EV after the failure of platinum-based chemotherapy and immune checkpoint inhibitors from December 2021 to November 2024.Results: Twenty-eight patients (male, n=16; median age, 71 years) were enrolled. Dexamethasone 6.6 mg was administered intravenously prior to EV in six (21.4%) patients. There were no differences in the overall response and disease control rates between patients with and without steroid premedication (p=0.653 and p&gt;0.99, respectively). The progression-free survival was not significantly associated with or without steroid premedication (not estimable vs. 4.3 months, p=0.501). There were no marked differences in the incidence of all grades of EV-related cutaneous adverse events (AEs) between patients with and without steroid premedication (33.3% vs. 45.5%, p=0.673). There was no significant difference in the incidence of grade ≥3 EV-related cutaneous AEs between the patients with and without steroid premedication (16.7% vs. 36.4%, p=0.630). Multivariate analysis revealed that a performance status ≥2 was an independent prognostic factor for progression-free survival (hazard ratio=4.653, 95% confidence interval=1.263-17.140, p=0.021), and steroid premedication was not (p =0.869).Conclusion: In EV treatment, steroid premedication did not affect clinical outcomes. The incidence and severity of EV-related cutaneous toxicity tended to improve in patients who received steroid premedication, although no significant differences were observed.</style></abstract></record></records></xml>